
Primary Progressive MS: Myths vs. Facts
Misconceptions about primary progressive multiple sclerosis (PPMS) are common, especially since the condition can look different for everyone. Knowing what's true (and what's not) can help you feel more informed and empowered.
Primary progressive multiple sclerosis (PPMS) is a complex condition that looks different from person to person. Symptoms, experiences, and rates of progression can vary widely.
Because PPMS isn't as well-known as other types of multiple sclerosis (MS), myths and misconceptions often fill the gaps. That can make it harder to find trustworthy answers when you're trying to learn more about the condition.
Here, we break down some of the most common myths about PPMS and share the facts behind them.
Myth#1: There will never be a cure for PPMS
Fact: While there's no cure yet, treatment options are expanding, and research is ongoing.
In 2017, the Food and Drug Administration (FDA) approved Ocrevus (ocrelizumab) as the first disease-modifying therapy (DMT) for PPMS.
In 2024, a new formulation called ocrelizumab and hyaluronidase-ocsq (Ocrevus Zunovo), a subcutaneous injection administered twice a year, was approved. This new injection offers a quicker, approximately 10-minute administration alternative to the traditional intravenous infusion.
Ocrevus and Ocrevus Zunovo are currently the only FDA-approved DMTs for PPMS. However, researchers are actively exploring new therapies. For instance, tolebrutinib, a Bruton's tyrosine kinase (BTK) inhibitor, is undergoing phase 3 trials to assess its potential in slowing PPMS progression.
Additionally, scientists are investigating treatments aimed at repairing myelin, the protective sheath around nerves damaged in MS. One such study involves combining metformin, a common diabetes medication, with clemastine, an antihistamine, to promote myelin repair. Myelin repair is important because it may help restore nerve function and slow disease progression.
Although a cure for PPMS has yet to be found, these developments reflect a growing commitment to improving treatment options and outcomes.
Myth: PPMS primarily occurs in females
Fact: PPMS affects people of all sexes at the same rate.
While relapsing-remitting multiple sclerosis (RRMS) is more common in people assigned female at birth (AFAB), affecting them two to three times more often than those assigned male at birth (AMAB), PPMS affects AFABs and AMABs in roughly equal numbers.
It's important not to assume the type of MS based solely on sex. Regardless of gender, if you experience symptoms suggestive of MS, consult a healthcare professional for an accurate diagnosis.
Myth: PPMS is an older person's disease
Fact: PPMS typically begins in mid-adulthood, not old age.
While PPMS tends to have a later onset than other forms of MS, it doesn't primarily affect older adults. On average, people with PPMS start experiencing symptoms around the age of 40.
Myth: A PPMS diagnosis means you'll be disabled
Fact: Disability progression in PPMS varies widely, and many people maintain mobility and independence for years.
PPMS can lead to physical disability, but how quickly or whether it develops looks different for everyone. Some people notice gradual changes, while others may stay stable for long stretches of time. Not everyone will need mobility aids like canes or wheelchairs, especially early on.
A 2022 study found that about 10% of people with MS experience severe disability within 5 years of diagnosis. That number rises to 25% within 10 years and then increases to 50% after 18 years.
Still, this doesn't mean you should expect disability after receiving a PPMS diagnosis. The location of lesions, your overall health, and how early you begin treatment can all play a role in how the condition progresses.
Working with your doctor on a treatment plan that includes physical or occupational therapy and regular movement can help you stay active and independent for longer.
Myth: Having PPMS means you have to quit your job
Fact: Many people with PPMS continue working, sometimes with a few adjustments.
A PPMS diagnosis doesn't automatically mean you need to stop working. While symptoms like fatigue, changes in memory or thinking, or mobility issues can make certain jobs more challenging, many people with PPMS continue in full- or part-time work, especially in the early stages.
Everyone's experience with PPMS is different, so your ability to work will depend on your specific symptoms and the demands of your job. If you're facing obstacles, workplace accommodations, like flexible hours, assistive devices, or ergonomic adjustments, may help you stay on the job.
A conversation with your doctor or a vocational (work) counselor who understands chronic conditions can also help you explore options that support your health and independence.
Myth: No medications help PPMS, so you should investigate natural remedies
Fact: There are FDA-approved medications that can help slow the progression of PPMS, including ocrelizumab. While some natural remedies might offer symptom relief, they aren't always safe or proven to be effective.
For years, there were no FDA-approved treatments for PPMS. That changed in 2017 when Ocrevus (ocrelizumab) became the first medication approved specifically for PPMS.
In a study of 732 people with PPMS, those who received Ocrevus experienced a slower rate of disability progression compared to those who received a placebo. It remains the only approved disease-modifying therapy for this form of MS.
Doctors may also prescribe medications to manage specific symptoms, such as antidepressants for mood changes or muscle relaxants for spasms.
Some people turn to natural remedies like herbal supplements, acupuncture, or cannabis. Research into these options is ongoing, but so far, there's no strong evidence that they're safe or effective for treating MS symptoms. Some supplements can even interact with prescription drugs.
If you're considering natural treatments, talk with your doctor first to avoid potential side effects or interactions.
Myth: PPMS is ultimately an isolating disease — no one will understand what you're going through
Fact: You're not alone, and you don't have to go through it alone either.
While PPMS can feel isolating at times, many others are navigating similar challenges. It's estimated that nearly 1 million people in the United States are living with MS, and about 10% to 15% of them have PPMS.
Thanks to growing awareness and advocacy, there are now more resources and support networks than ever. Support groups, both in-person and online, offer a space to connect with others who understand what you're going through.
If group support isn't for you, that's OK too. Talking with a trusted friend, loved one, or therapist can still help ease feelings of isolation and improve emotional well-being. What matters most is finding a form of support that feels right for you.
Myth: PPMS is deadly
Fact: PPMS is a lifelong condition, but it's rarely fatal.
The progressive nature of PPMS and the fact that there's no cure can understandably lead to fears about long-term outcomes. But while PPMS can affect mobility, thinking, and daily functioning, it's not considered a life threatening illness.
Most people with MS who don't have severe disabilities can expect to live another 30 to 35 years after diagnosis. Recent research has shown that even after significant disease progression, many people continue to live for years. For example, after someone loses the ability to walk independently, on average, at around age 51, life expectancy is about 13 more years.
Advances in treatment, early intervention, and lifestyle changes can help manage symptoms, reduce complications, and support overall health.
Taking care of your physical and emotional well-being through exercise, a balanced diet, regular checkups, and support can make a big difference in quality of life.
It's important to note that with ongoing advances in treatment, the outlook for people with PPMS continues to improve. Current data on disability and life expectancy may not reflect what's possible in the future.
Takeaway
Misconceptions about primary progressive multiple sclerosis (PPMS) can add confusion and fear to an already complex condition. However, the reality is that PPMS doesn't always follow the path people expect.
From treatment options to life expectancy, the facts paint a more hopeful and nuanced picture. While every experience with PPMS is different, understanding the reality behind the myths can help you make informed choices, find support, and feel more in control of your journey.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
23 minutes ago
- Yahoo
Fapon Biopharma to Showcase Differentiated Pipeline, Including Phase 1 Immunocytokine FP008, and Innovative Technology Platforms at BIO 2025
BOSTON, June 12, 2025 /PRNewswire/ -- Fapon Biopharma, a clinical-stage biotech company innovating therapeutic antibodies and fusion proteins, is pleased to announce its participation in the BIO International Convention 2025 (BIO 2025), taking place June 16-19 in Boston Convention & Exhibition Center. The company will exhibit at Booth #1851, presenting its differentiated pipeline, including the flagship Phase 1 immunocytokine FP008, a portfolio of promising early-stage candidates for oncology and autoimmune diseases, and its suite of proprietary technology platforms, while actively seeking global partnerships. FP008, Fapon Biopharma's lead asset, is a first-in-class immunocytokine currently in Phase 1 clinical trials, designed to address significant unmet needs in solid tumor patient refractory to anti-PD-1 therapy. The company will also feature promising preclinical candidates targeting oncology (FP010, FP011, FPE021) and autoimmune diseases (FPE022, FPE024), highlighting its expanding research capabilities. Fapon Biopharma will feature its proprietary and innovative technology platforms, engineered to overcome complex drug development challenges: Bi/Tri-TCE Platform: Human-monkey cross-reactive TCR/CD3 nanobody, enabling the design of potent multi-specific antibodies for targeted cancer immunotherapy. FILTEN™ (IL-10M Fusion Protein Platform): Overcoming IL-10 limitations for broad applications in cancer and autoimmune diseases PROTiNb™ (Proteolysis Targeting Intra-Nanobody): A pioneering platform targeting previously "undruggable" intracellular targets, demonstrating a strong competitive edge. FIND™ Mammalian Cell Display Platform: Accelerating antibody discovery by combining mammalian cell expression with high-throughput screening. "We are excited to connect with the global biopharma community at BIO 2025," said Vincent Huo, President of Fapon Biopharma. "We look forward to demonstrating the exciting progress of our internal pipeline and how our technology platforms can empower external partners to bring transformative therapy to patients faster." Engagement Opportunities:Exhibition Booth: #1851Company Presentation: Time: 11:30 a.m., Tuesday, June 17, 2025Location: Room 153A, Boston Convention & Exhibition Center To schedule a meeting in advance or during the conference, please contact our BD representatives, Max Wang ( and Liyan Gao ( or visit us at Booth #1851. Meetings can also be requested via the BIO partnering system. About Fapon Biopharma ( Fapon Biopharma specializes in discovering and developing biologics for treating cancers, autoimmune diseases and other diseases where there are unmet medical needs. Leveraging cutting-edge technologies, we have built advanced drug discovery platforms, including an antibody discovery platform based on the globally leading mammalian cell display technology, a platform for generating IL-10M fusion proteins, and a platform for developing multispecific antibodies using Fibody and nanobodies. With a differentiated pipeline of leading drug candidates, we have established capabilities that cover the entire drug development process from drug discovery, preclinical research, Chemistry, Manufacturing and Controls (CMC) to early clinical development. Committed to innovation, we strive to deliver safer, more efficacious, affordable, and accessible biologics for everyone. View original content to download multimedia: SOURCE Fapon Biopharma Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Yahoo
29 minutes ago
- Yahoo
Frederick County Health Department to offer free HIV testing
The Frederick County Health Department will offer free HIV testing as part of National HIV Testing Day this month. The free testing event will take place between 10 a.m. and 6:30 p.m. on June 27 at the Walgreens on Opossumtown Pike. The Frederick County Health Department staff will be available during the event to answer questions, provide education and connect people to additional prevention and care services such as pre-exposure prophylaxis (PReP). PReP is a medication that can reduce the risk of transmission in the event of an HIV exposure. National HIV Testing Day was first observed on June 27, 1995, according to The purpose of the day is 'to encourage people to get tested for HIV, know their status, and get linked to care and treatment.' Between 2019 and 2023, 66 people in Frederick County were diagnosed with HIV, according to data from the Maryland Department of Health's Infectious Disease Prevention and Health Services Bureau. For the majority of people diagnosed in that time frame, the HIV infection had not progressed to AIDS. Outside of the June 27 event, the Frederick County Health Department offers free walk-in testing on Tuesdays and Fridays from 9 a.m. to 3 p.m. and by appointment by calling 301-600-3117. All tests are confidential. More information about HIV services in Frederick County can be found at — Ceoli Jacoby


Medscape
38 minutes ago
- Medscape
Cannabis Use Common in Teens With Chronic Pain, Study Finds
Roughly one quarter of teens presenting at a pain clinic reported using cannabis, with the majority saying they used the drug to cope with symptoms related to chronic pain, according to new findings published in JAMA Network Open . These teens used the drug to alleviate their physical symptoms, as well as anxiety, poor sleep, or nausea. Researchers said teenagers who use marijuana increase their risk of developing adverse effects associated with the drug, such as worsening anxiety and depression. 'What concerns me most is the heightened risk of developing cannabis use disorder,' said Joe Kossowsky, PhD, MMSc, an assistant professor of anesthesia at Harvard Medical School in Boston, the lead author of the study. The rising potency of tetrahydrocannabinol, the main psychoactive substance in cannabis, may compound the risks for adverse effects among youth who use the drug, he said. Kossowsky said he conducted the research to find out the extent to which teens with chronic pain used marijuana. Between 2021 and 2024, he and his colleagues recruited teens aged 14-19 years with diagnosed chronic pain conditions from a Boston pediatric pain clinic. Of 245 teens, 14 said they had used cannabis for recreational purposes and 48 said they had used the drug to manage their chronic pain. The participants in the study completed surveys detailing the characteristics of their pain, frequency and reason for cannabis use, adverse effects, and beliefs around cannabis. They also filled out surveys detailing the extent to which pain interfered with daily activities such as running or standing, called pain interference. The age of first cannabis use ranged from age 7-19 years (mean age, 15.3 years). Overall, teens reported having used cannabis over the previous year on a median of six to nine occasions. Most teens used edibles (51.6%), vapes (45.2%), and joints (43.5%) to consume marijuana. The group younger than 18 years who said they had used cannabis for any reason reported slightly higher scores of pain interference than the group that had not used the drug. Their depressive symptoms scores were also higher than those who had not used. Youth using marijuana to manage symptoms were a year younger on average than those who said they used it recreationally (mean difference, −0.7 years; 95% CI, −1.3 to −0.1 years; P = .04) and also reported greater functional disability (mean difference, 8.4; 95% CI, 2.1-12.6; P = .01). Kossowsky told Medscape Medical News that he also found that those using marijuana to manage symptoms consumed it more frequently and had started at a younger age than those who used it recreationally; findings that were not included in the current research but that he said he plans on publishing in another study. Initially, cannabis affects the endocannabinoid system, decreasing pain at the level of peripheral nerves, the spinal cord, and the brain. 'It does initially provide the relief that they're looking for,' Kossowsky said. But the nerve receptors in these areas become less responsive over time, necessitating heavier use of the drug to achieve the same level of relief. This cycle can increase the risk that a teen develops cannabis use disorder, Kossowsky said. The long-term consequences of cannabis use are amplified during the developmental window of adolescence, said Sharon Levy, MD, chief of the Division of Addiction Medicine at Boston Children's Hospital, Boston. The part of the brain that pursues pleasure is developing rapidly, and dopamine receptors that signal pleasure are at their lifetime densest. 'There's a drive to do things that are going to cause a lot of dopamine firing,' which can include using cannabis, Levey said. Meanwhile, the prefrontal cortex, the seat of executive functions that supports sound decision-making, is still immature and cannot be counted on for reliable input, Levy said. This developmental imbalance is the reason that substance use is particularly common among adolescents, Levy said. Cannabis use during adolescence is associated with worse functional outcomes, such as diminished verbal memory and attention, poorer educational achievements, mental health disorders like anxiety, depression, psychosis, and addiction. Kossowsky said he hopes his study will alert clinicians to the challenges faced by adolescents with chronic pain. 'I'm hoping there will definitely be more screening done and interventional work,' he said. Participants in the study who used cannabis to manage chronic pain tended to think that the drug was safe because it was natural, the study showed. By contrast, their peers who did not consume cannabis were more aware of the risks of such usage, including worsening their medical problems and developing addiction to the substance. Clinicians should also treat the pain, anxiety, and disrupted sleep that prompts patients to use cannabis. 'You can't take that away from them without providing them with something else that helps,' Kossowsky said. The first-line treatment is an integrative approach combining cognitive behavior therapy with physiotherapy. Medications can be added as needed, such as selective serotonin reuptake inhibitors to alleviate anxiety. Kossowsky said he is currently tracking the same cohort of teens with chronic pain over 5 years. 'This study is a first effort to shed light on a complex issue,' Kossowsky said. 'But now what we're seeing has definitely warranted going a step further.' This study was funded by the National Institute on Drug Abuse. The researchers reported no relevant financial conflicts of interest.